BeBetter Med (688759) Stock Overview
A biopharmaceutical company, engages in the research and development, and sale of drugs for tumors, autoimmune diseases, and metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
688759 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BeBetter Med Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥29.70 |
| 52 Week High | CN¥48.91 |
| 52 Week Low | CN¥29.47 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688759 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.1% | 3.8% | -0.5% |
| 1Y | n/a | 20.9% | 21.5% |
Return vs Industry: Insufficient data to determine how 688759 performed against the CN Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 688759 performed against the CN Market.
Price Volatility
| 688759 volatility | |
|---|---|
| 688759 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in CN Market | 9.3% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 688759's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: Insufficient data to determine 688759's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Changgeng Qian | www.bebettermed.cn |
BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for tumors, autoimmune diseases, and metabolic diseases. It is developing BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; BEBT-209, a CDK4 highly selective CDK4/6 inhibitor for antitumor; BEBT-109, a pan-mutant EGFR inhibitor for antitumor; BEBT-260, a ChK1 inhibitor for antitumor; BEBT-305, a second-generation HSP90 inhibitor for autoimmune disease; BEBT-503, a pan-PPAR agonist for metabolic disease; BEBT-607, a KRAS G12C inhibitor for antitumor; BEBT-808, an oral small molecule GLP-1R full agonist for metabolic disease; BEBT-809, a GPR75 pathway inhibitor for metabolic disease; and BEBT-508, a small nucleic acid drug. The company was founded in 2012 and is based in Guangzhou, China.
BeBetter Med Inc. Fundamentals Summary
| 688759 fundamental statistics | |
|---|---|
| Market cap | CN¥13.37b |
| Earnings (TTM) | -CN¥56.00m |
| Revenue (TTM) | n/a |
Is 688759 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688759 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥56.00m |
| Earnings | -CN¥56.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1.4% |
How did 688759 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 07:35 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BeBetter Med Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.